Relapsing babesiosis with molecular evidence of resistance to certain antimicrobials commonly used to treat <i>Babesia microti</i> infections

Abstract Human babesiosis cases are emerging with an increased incidence and a wider geographic range worldwide. Relapsing becoming more frequently encountered in clinical practice associated the use of immunosuppressive medications. The 2020 Infectious Diseases Society America guidelines recommends at least 6 weeks antimicrobial treatment for highly immunocompromised patients Babesia microti infection. Nevertheless, have relapsed even after treatment. Genetic mutations regarded as potential cause resistance B. been identified certain relapsing cases. A few alternative regimens used successfully to achieve cure some these cases, but other had fatal outcomes. In this review, we discuss molecular evidence genetic antimicrobials commonly treat infections based on evaluation 9